H. R. 6—224 
SEC. 8216. DEFINITIONS. 
Section 702 of the Office of National Drug Control Policy 
Reauthorization Act of 1998 (21 U.S.C. 1701) is amended— 
(1) by striking paragraphs (5), (12), and (13); 
(2) by redesignating paragraph (11) as paragraph (17); 
(3) by redesignating paragraphs (9) and (10) as paragraphs 
(14) and (15), respectively; 
(4) by redesignating paragraphs (6), (7), and (8) as para-
graphs (10), (11), and (12), respectively; 
(5) by redesignating paragraphs (1), (2), (3), and (4) as 
paragraphs (3), (4), (5), and (6), respectively; 
(6) by inserting before paragraph (3), as so redesignated, 
the following: 
‘‘(1) AGENCY.—The term ‘agency’ has the meaning given 
the term ‘executive agency’ in section 102 of title 31, United 
States Code. 
‘‘(2) APPROPRIATE CONGRESSIONAL COMMITTEES.— 
‘‘(A) IN GENERAL.—The term ‘appropriate congressional 
committees’ means— 
‘‘(i) the Committee on the Judiciary, the Committee 
on Appropriations, and the Committee on Health, Edu-
cation, Labor, and Pensions of the Senate; and 
‘‘(ii) the Committee on Oversight and Government 
Reform, the Committee on the Judiciary, the Com-
mittee on Energy and Commerce, and the Committee 
on Appropriations of the House of Representatives. 
‘‘(B) SUBMISSION
TO
CONGRESS.—Any submission to 
Congress shall mean submission to the appropriate 
congressional committees.’’; 
(7) by amending paragraph (3), as so redesignated, to read 
as follows: 
‘‘(3) DEMAND
REDUCTION.—The term ‘demand reduction’ 
means any activity conducted by a National Drug Control Pro-
gram Agency, other than an enforcement activity, that is 
intended to reduce or prevent the use of drugs or support, 
expand, or provide treatment and recovery efforts, including— 
‘‘(A) education about the dangers of illicit drug use; 
‘‘(B) services, programs, or strategies to prevent sub-
stance use disorder, including evidence-based education 
campaigns, community-based prevention programs, collec-
tion and disposal of unused prescription drugs, and services 
to at-risk populations to prevent or delay initial use of 
an illicit drug; 
‘‘(C) substance use disorder treatment; 
‘‘(D) support for long-term recovery from substance 
use disorders; 
‘‘(E) drug-free workplace programs; 
‘‘(F) drug testing, including the testing of employees; 
‘‘(G) interventions for illicit drug use and dependence; 
‘‘(H) expanding availability of access to health care 
services for the treatment of substance use disorders; 
‘‘(I) international drug control coordination and 
cooperation with respect to activities described in this para-
graph; 
‘‘(J) pre- and post-arrest criminal justice interventions 
such as diversion programs, drug courts, and the provision 
of evidence-based treatment to individuals with substance
H. R. 6—225 
use disorders who are arrested or under some form of 
criminal justice supervision, including medication assisted 
treatment; 
‘‘(K) other coordinated and joint initiatives among Fed-
eral, State, local, and Tribal agencies to promote com-
prehensive drug control strategies designed to reduce the 
demand for, and the availability of, illegal drugs; 
‘‘(L) international illicit drug use education, prevention, 
treatment, recovery, research, rehabilitation activities, and 
interventions for illicit drug use and dependence; and 
‘‘(M) research related to illicit drug use and any of 
the activities described in this paragraph.’’; 
(8) by inserting after paragraph (6), as so redesignated, 
the following: 
‘‘(7) EMERGING DRUG THREAT.—The term ‘emerging drug 
threat’ means the occurrence of a new and growing trend in 
the use of an illicit drug or class of drugs, including rapid 
expansion in the supply of or demand for such drug. 
‘‘(8) ILLICIT DRUG USE; ILLICIT DRUGS; ILLEGAL DRUGS.— 
The terms ‘illicit drug use’, ‘illicit drugs’, and ‘illegal drugs’ 
include the illegal or illicit use of prescription drugs. 
‘‘(9) LAW ENFORCEMENT.—The term ‘law enforcement’ or 
‘drug law enforcement’ means all efforts by a Federal, State, 
local, or Tribal government agency to enforce the drug laws 
of the United States or any State, including investigation, 
arrest, prosecution, and incarceration or other punishments 
or penalties.’’; 
(9) by amending paragraph (11), as so redesignated, to 
read as follows: 
‘‘(11) NATIONAL
DRUG
CONTROL
PROGRAM
AGENCY.—The 
term ‘National Drug Control Program Agency’ means any 
agency (or bureau, office, independent agency, board, division, 
commission, subdivision, unit, or other component thereof) that 
is responsible for implementing any aspect of the National 
Drug Control Strategy, including any agency that receives Fed-
eral funds to implement any aspect of the National Drug Con-
trol Strategy, but does not include any agency that receives 
funds for drug control activity solely under the National Intel-
ligence Program or the Joint Military Intelligence Program.’’; 
(10) in paragraph (12), as so redesignated— 
(A) by inserting ‘‘or ‘Strategy’ ’’ before ‘‘means’’; and 
(B) by inserting ‘‘, including any report, plan, or 
strategy required to be incorporated into or issued concur-
rently with such strategy’’ before the period at the end; 
(11) by inserting after paragraph (12), as so redesignated, 
the following: 
‘‘(13) NONPROFIT
ORGANIZATION.—The term ‘nonprofit 
organization’ means an organization that is described in section 
501(c)(3) of the Internal Revenue Code of 1986 and exempt 
from tax under section 501(a) of such Code.’’; 
(12) in paragraph (14), as so redesignated, by striking 
‘‘Unless the context clearly indicates otherwise, the’’ and 
inserting ‘‘The’’; 
(13) by inserting after paragraph (15), as so redesignated, 
the following: 
‘‘(16) SUBSTANCE
USE
DISORDER
TREATMENT.—The term 
‘substance use disorder treatment’ means an evidence-based,
H. R. 6—226 
professionally directed, deliberate, and planned regimen 
including evaluation, observation, medical monitoring, and 
rehabilitative 
services 
and 
interventions 
such 
as 
pharmacotherapy, behavioral therapy, and individual and group 
counseling, on an inpatient or outpatient basis, to help patients 
with substance use disorder reach recovery.’’; and 
(14) in paragraph (17), as so redesignated— 
(A) by redesignating subparagraphs (B), (C), (D), and 
(E), as subparagraphs (C), (D), (E), and (F), respectively; 
(B) by inserting after subparagraph (A) the following: 
‘‘(B) domestic law enforcement;’’; 
(C) in subparagraph (E), as so redesignated, by striking 
‘‘and’’ at the end; 
(D) in subparagraph (F), as so redesignated, by striking 
the period at the end and inserting a semicolon; and 
(E) by adding at the end the following: 
‘‘(G) activities to prevent the diversion of drugs for 
their illicit use; and 
‘‘(H) research related to any of the activities described 
in this paragraph.’’. 
SEC. 8217. AMENDMENTS TO ADMINISTRATION OF THE OFFICE. 
(a) RESPONSIBILITIES OF OFFICE.—Section 703(a) of the Office 
of National Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1702(a)) is amended— 
(1) by striking paragraph (1) and inserting the following: 
‘‘(1) lead the national drug control effort, including coordi-
nating with the National Drug Control Program Agencies;’’; 
(2) in paragraph (2), by inserting before the semicolon 
the following: ‘‘, including the National Drug Control Strategy’’; 
(3) in paragraph (3), by striking ‘‘and’’ at the end; and 
(4) by striking paragraph (4) and all that follows through 
‘‘the National Academy of Sciences.’’ and inserting the following: 
‘‘(4) evaluate the effectiveness of national drug control 
policy efforts, including the National Drug Control Program 
Agencies’ program, by developing and applying specific goals 
and performance measurements and monitoring the agencies’ 
program-level spending; 
‘‘(5) identify and respond to emerging drug threats related 
to illicit drug use; 
‘‘(6) administer the Drug-Free Communities Program, the 
High-Intensity Drug Trafficking Areas Program, and other 
grant programs directly authorized to be administered by the 
Office in furtherance of the National Drug Control Strategy; 
and 
‘‘(7) facilitate broad-scale information sharing and data 
standardization among Federal, State, and local entities to 
support the national drug control efforts.’’. 
(b) ETHICS GUIDELINES.—Section 703(d) of the Office of National 
Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1702(d)) 
is amended by adding at the end the following: 
‘‘(4) ETHICS GUIDELINES.—The Director shall establish writ-
ten guidelines setting forth the criteria to be used in deter-
mining whether a gift or donation should be declined under 
this subsection because the acceptance of the gift or donation 
would—
H. R. 6—227 
‘‘(A) reflect unfavorably upon the ability of the Director 
or the Office, or any employee of the Office, to carry out 
responsibilities or official duties under this chapter in a 
fair and objective manner; or 
‘‘(B) compromise the integrity or the appearance of 
integrity of programs or services provided under this 
chapter or of any official involved in those programs or 
services. 
‘‘(5) REGISTRY OF GIFTS.—The Director shall maintain a 
list of— 
‘‘(A) the source and amount of each gift or donation 
accepted by the Office; and 
‘‘(B) the source and amount of each gift or donation 
accepted by a contractor to be used in its performance 
of a contract for the Office. 
‘‘(6) REPORT TO CONGRESS.—The Director shall include in 
the annual assessment under section 706(g) a copy of the reg-
istry maintained under paragraph (5).’’. 
(c) APPOINTMENT OF DIRECTOR AND DEPUTY DIRECTOR.—Section 
704(a) of the Office of National Drug Control Policy Reauthorization 
Act of 1998 (21 U.S.C. 1703(a)) is amended— 
(1) in paragraph (1), by striking subparagraphs (A), (B), 
and (C), and inserting the following: 
‘‘(A) DIRECTOR.— 
‘‘(i) IN GENERAL.—There shall be at the head of 
the Office a Director who shall hold the same rank 
and status as the head of an executive department 
listed in section 101 of title 5, United States Code. 
‘‘(ii) 
APPOINTMENT.—The 
Director 
shall 
be 
appointed by the President, by and with the advice 
and consent of the Senate, and shall serve at the 
pleasure of the President. 
‘‘(B) DEPUTY
DIRECTOR.—There shall be a Deputy 
Director who shall report directly to the Director, and 
who shall be appointed by the President, and shall serve 
at the pleasure of the President. 
‘‘(C) COORDINATORS.—The following coordinators shall 
be appointed by the Director: 
‘‘(i) Performance Budget Coordinator, as described 
in section 704(c)(4). 
‘‘(ii) Interdiction Coordinator, as described in sec-
tion 711. 
‘‘(iii) Emerging and Continuing Threats Coordi-
nator, as described in section 709. 
‘‘(iv) State, Local, and Tribal Affairs Coordinator, 
to carry out the activities described in section 704(j). 
‘‘(v) Demand Reduction Coordinator, as described 
in subparagraph (D). 
‘‘(D) DEMAND REDUCTION COORDINATOR.—The Director 
shall designate or appoint a United States Demand Reduc-
tion Coordinator to be responsible for the activities 
described in section 702(3). The Director shall determine 
whether the coordinator position is a noncareer appointee 
in the Senior Executive Service or a career appointee in 
a position at level 15 of the General Schedule (or equiva-
lent).’’;
H. R. 6—228 
(2) in paragraph (5), by striking ‘‘such official’’ and inserting 
‘‘such officer or employee’’; and 
(3) by adding at the end the following: 
‘‘(6) PROHIBITION ON THE USE OF FUNDS FOR BALLOT INITIA-
TIVES.—No funds authorized under this title may be obligated 
for the purpose of expressly advocating the passage or defeat 
of a State or local ballot initiative.’’. 
(d) CONSULTATION.—Section 704(b) of the Office of National 
Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1703(b)) 
is amended— 
(1) in paragraph (19), by striking ‘‘; and’’ and inserting 
a semicolon; 
(2) in paragraph (20), by striking the period at the end 
and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(21) in order to formulate the national drug control poli-
cies, goals, objectives, and priorities— 
‘‘(A) shall consult with and assist— 
‘‘(i) State and local governments; 
‘‘(ii) National Drug Control Program Agencies; 
‘‘(iii) each committee, working group, council, or 
other entity established under this chapter, as appro-
priate; 
‘‘(iv) the public; 
‘‘(v) appropriate congressional committees; and 
‘‘(vi) any other person in the discretion of the 
Director; and 
‘‘(B) may— 
‘‘(i) establish advisory councils; 
‘‘(ii) acquire data from agencies; and 
‘‘(iii) request data from any other entity.’’. 
(e) NATIONAL
DRUG
CONTROL
PROGRAM
BUDGET.—Section 
704(c) of the Office of National Drug Control Policy Reauthorization 
Act of 1998 (21 U.S.C. 1703(c)) is amended— 
(1) in paragraph (2)— 
(A) in subparagraph (A), by striking ‘‘paragraph (1)(C);’’ 
and inserting the following: ‘‘paragraph (1)(C) and 
include— 
‘‘(i) the funding level for each National Drug Con-
trol Program agency; and 
‘‘(ii) alternative funding structures that could 
improve progress on achieving the goals fo the National 
Drug Control Strategy; and’’; 
(B) in subparagraph (B), strike ‘‘the President; and’’ 
and inserting ‘‘the President and Congress.’’; and 
(C) by striking subparagraph (C); 
(2) in paragraph (3)(E), by striking clause (ii) and inserting 
the following: 
‘‘(ii) CERTIFICATION.—The Director shall— 
‘‘(I) review each budget submission submitted 
under subparagraph (A); 
‘‘(II) based on the review under clause (i), 
make a determination as to whether the budget 
submission of a National Drug Control Program 
agency includes the funding levels and initiatives 
described in subparagraph (B); and
H. R. 6—229 
‘‘(III) submit to the appropriate congressional 
committees— 
‘‘(aa) a written statement that either— 
‘‘(AA) 
certifies 
that 
the 
budget 
submission includes sufficient funding; or 
‘‘(BB) decertifies the budget submis-
sion as not including sufficient funding; 
‘‘(bb) a copy of the description made under 
subparagraph (B); and 
‘‘(cc) the budget recommendations made 
under subsection (b)(8).’’; and 
(3) by adding at the end the following: 
‘‘(5) PERFORMANCE-BUDGET COORDINATOR.— 
‘‘(A) DESIGNATION.—The Director shall designate or 
appoint a United States Performance-Budget Coordinator 
to— 
‘‘(i) ensure the Director has sufficient information 
necessary to analyze the performance of each National 
Drug Control Program Agency, the impact Federal 
funding has had on the goals in the Strategy, and 
the likely contributions to the goals of the Strategy 
based on funding levels of each National Drug Control 
Program Agency, to make an independent assessment 
of the budget request of each agency under this sub-
section; 
‘‘(ii) advise the Director on agency budgets, 
performance measures and targets, and additional data 
and research needed to make informed policy decisions 
under this section and section 706; and 
‘‘(iii) other duties as may be determined by the 
Director with respect to measuring or assessing 
performance or agency budgets. 
‘‘(B) DETERMINATION OF POSITION.—The Director shall 
determine whether the coordinator position is a noncareer 
appointee in the Senior Executive Service or a career 
appointee in a position at level 15 of the General Schedule 
(or equivalent). 
‘‘(6) BUDGET ESTIMATE OR REQUEST SUBMISSION TO CON-
GRESS.—Whenever the Director submits any budget estimate 
or request to the President or the Office of Management and 
Budget, the Director shall concurrently transmit to the appro-
priate congressional committees a detailed statement of the 
budgetary needs of the Office to execute its mission based 
on the good-faith assessment of the Director.’’. 
(f) POWERS AND RESPONSIBILITIES OF THE DIRECTOR.—Section 
704 of the Office of National Drug Control Policy Reauthorization 
Act of 1998 (21 U.S.C. 1703) is amended— 
(1) in subsection (d)(8)— 
(A) in subparagraph (D), by striking ‘‘and’’ at the end; 
(B) in subparagraph (E)— 
(i) in clause (i)— 
(I) by striking ‘‘Congress, including to the 
Committees on Appropriations of the Senate and 
the House of Representatives, the authorizing 
committees for the Office,’’ and inserting ‘‘the 
appropriate congressional committees’’; and 
(II) by striking ‘‘or agencies’’;
H. R. 6—230 
(ii) in clause (ii)— 
(I) by striking ‘‘Congress’’ and inserting ‘‘the 
appropriate congressional committees’’; and 
(II) by adding ‘‘and’’ at the end; and 
(iii) by adding at the end the following: 
‘‘(iii) funds may only be used for— 
‘‘(I) expansion of demand reduction activities; 
‘‘(II) interdiction of illicit drugs on the high 
seas, in United States territorial waters, and at 
United States ports of entry by officers and 
employees of National Drug Control Program 
Agencies and domestic and foreign law enforce-
ment officers; 
‘‘(III) accurate assessment and monitoring of 
international drug production and interdiction pro-
grams and policies; 
‘‘(IV) activities to facilitate and enhance the 
sharing of domestic and foreign intelligence 
information among National Drug Control Pro-
gram Agencies related to the production and traf-
ficking of drugs in the United States and foreign 
countries; and 
‘‘(V) research related to any of these activi-
ties.’’; 
(2) in subsection (e)(2)(A), by striking ‘‘Notwithstanding 
any other provision of law’’ and inserting ‘‘Subject to the avail-
ability of appropriations’’; and 
(3) by adding at the end the following: 
‘‘(i) MODEL ACTS PROGRAM.— 
‘‘(1) IN GENERAL.—The Director shall provide for or shall 
enter into an agreement with a nonprofit organization to— 
‘‘(A) advise States on establishing laws and policies 
to address illicit drug use issues; and 
‘‘(B) revise such model State drug laws and draft 
supplementary model State laws to take into consideration 
changes in illicit drug use issues in the State involved. 
‘‘(2) AUTHORIZATION OF APPROPRIATIONS.—There is author-
ized to be appropriated to carry out this subsection $1,250,000 
for each of fiscal years 2018 through 2023. 
‘‘(j) STATE, LOCAL, AND TRIBAL AFFAIRS COORDINATOR.—The 
Director shall designate or appoint a United States State, Local, 
and Tribal Affairs Coordinator to perform the duties of the Office 
outlined in this section and 706 and such other duties as may 
be determined by the Director with respect to coordination of drug 
control efforts between agencies and State, local, and Tribal govern-
ments. The Director shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Executive Service or 
a career appointee in a position at level 15 of the General Schedule 
(or equivalent). 
‘‘(k) HARM
REDUCTION
PROGRAMS.—When developing the 
national drug control policy, any policy of the Director, including 
policies relating to syringe exchange programs for intravenous drug 
users, shall be based on the best available medical and scientific 
evidence regarding the effectiveness of such policy in promoting 
individual health and preventing the spread of infectious disease 
and the impact of such policy on drug addiction and use. In making 
any policy relating to harm reduction programs, the Director shall
H. R. 6—231 
consult with the National Institutes of Health and the National 
Academy of Sciences.’’. 
(g) ACCOUNTING
OF FUNDS EXPENDED.—Section 705 of the 
Office of National Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1704(d)), as amended by section 8207 is further 
amended— 
(1) by amending subsection (d) to read as follows: 
‘‘(d) ACCOUNTING OF FUNDS EXPENDED.— 
‘‘(1) IN GENERAL.—Not later than February 1 of each year, 
in accordance with guidance issued by the Director, the head 
of each National Drug Control Program Agency shall submit 
to the Director a detailed accounting of all funds expended 
by the agency for National Drug Control Program activities 
during the previous fiscal year and shall ensure such detailed 
accounting is authenticated for the previous fiscal year by the 
Inspector General for such agency prior to the submission to 
the Director as frequently as determined by the Inspector Gen-
eral but not less frequently that every 3 years. 
‘‘(2) SUBMISSION TO CONGRESS.—The Director shall submit 
to Congress not later than April 1 of each year the information 
submitted to the Director under paragraph (1).’’; and 
(2) by adding at the end the following: 
‘‘(f) TRACKING SYSTEM FOR FEDERALLY FUNDED GRANT PRO-
GRAMS.— 
‘‘(1) ESTABLISHMENT.—The Director, or the head of an 
agency designated by the Director, in coordination with the 
Secretary of Health and Human Services, shall track federally- 
funded grant programs to— 
‘‘(A) ensure the public has electronic access to informa-
tion identifying: 
‘‘(i) all drug control grants and pertinent identi-
fying information for each grant; 
‘‘(ii) any available performance metrics, evalua-
tions, or other information indicating the effectiveness 
of such programs; 
‘‘(B) facilitate efforts to identify duplication, overlap, 
or gaps in funding to provide increased accountability of 
Federally-funded grants for substance use disorder treat-
ment, prevention, and enforcement; and 
‘‘(C) identify barriers in the grant application process 
impediments that applicants currently have in the grant 
application process with applicable agencies. 
‘‘(2) NATIONAL DRUG CONTROL AGENCIES.—The head of each 
National Drug Control Program Agency shall provide to the 
Director a complete list of all drug control program grant pro-
grams and any other relevant information for inclusion in the 
system developed under paragraph (1) and annually update 
such list. 
‘‘(3) UPDATING EXISTING SYSTEMS.—The Director may meet 
the requirements of this subsection by utilizing, updating, or 
improving existing Federal information systems to ensure they 
meet the requirements of this subsection. 
‘‘(4) REPORT.—Not later than 3 years after the date of 
enactment of this subsection, the Comptroller General of the 
United States shall submit to Congress a report examining 
implementation of this subsection.’’.
H. R. 6—232 
(h) TECHNICAL AND CONFORMING AMENDMENT.—Section 1105 
of the Office of National Drug Control Policy Reauthorization Act 
of 2006 (21 U.S.C. 1701 note) is repealed. 
SEC. 8218. EMERGING THREATS COMMITTEE, PLAN, AND MEDIA CAM-
PAIGN. 
(a) IN GENERAL.—Section 709 of the Office of National Drug 
Control Policy Reauthorization Act of 1998 (21 U.S.C. 1708) is 
amended to read as follows: 
‘‘SEC. 709. EMERGING THREATS COMMITTEE, PLAN, AND MEDIA CAM-
PAIGN. 
‘‘(a) EMERGING THREATS COORDINATOR.—The Director shall des-
ignate or appoint a United States Emerging and Continuing Threats 
Coordinator to perform the duties of that position described in 
this section and such other duties as may be determined by the 
Director. The Director shall determine whether the coordinator 
position is a noncareer appointee in the Senior Executive Service 
or a career appointee in a position at level 15 of the General 
Schedule (or equivalent). 
‘‘(b) EMERGING THREATS COMMITTEE.— 
‘‘(1) IN
GENERAL.—The Emerging Threats Committee 
shall— 
‘‘(A) monitor evolving and emerging drug threats in 
the United States; 
‘‘(B) identify and discuss evolving and emerging drug 
trends in the United States using the criteria required 
to be established under paragraph (6); 
‘‘(C) assist in the formulation of and oversee 
implementation of any plan described in subsection (d); 
‘‘(D) provide such other advice to the Coordinator and 
Director concerning strategy and policies for emerging drug 
threats and trends as the Committee determines to be 
appropriate; and 
‘‘(E) disseminate and facilitate the sharing with Fed-
eral, State, local, and Tribal officials and other entities 
as determined by the Director of pertinent information 
and data relating to— 
‘‘(i) recent trends in drug supply and demand; 
‘‘(ii) fatal and nonfatal overdoses; 
‘‘(iii) demand for and availability of evidence-based 
substance use disorder treatment, including the extent 
of the unmet treatment need, and treatment admission 
trends; 
‘‘(iv) recent trends in drug interdiction, supply, 
and demand from State, local, and Tribal law enforce-
ment agencies; and 
‘‘(v) other subject matter as determined necessary 
by the Director. 
‘‘(2) CHAIRPERSON.—The Director shall designate one of 
the members of the Emerging Threats Committee to serve 
as Chairperson. 
‘‘(3) MEMBERS.—The Director shall appoint other members 
of the Committee, which shall include— 
‘‘(A) representatives from National Drug Control Pro-
gram Agencies or other agencies; 
‘‘(B) representatives from State, local, and Tribal 
governments; and